4.775EUR-0.73%Mkt Cap: 998.79M EURP/E: —Last update: 2026-05-14
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in F…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-6.31
PEG—
P/B-32.50
P/S147.73
EV/EBITDA-8.53
EV/Revenue167.15
EPS (TTM)-1.90
EPS (Forward)-0.76
Cash Flow & Leverage
FCF Yield-20.10%
FCF Margin-2968.67%
Operating CF-104.88M EUR
CapEx (TTM)247.00K EUR
Net Debt/EBITDA-0.99
Net Debt131.05M EUR
Technical
SMA 504.811 (-0.8%)
SMA 2004.411 (+8.3%)
Beta0.88
S&P 52W Chg24.23%
Avg Vol (30d)302.26K
Avg Vol (10d)294.55K
Technical Indicators
RSI (14)53.6
MACD0.0057
MACD Signal-0.0632
MACD Hist.+0.0689
BB Upper5.029 EUR
BB Middle4.581 EUR
BB Lower4.133 EUR
BB Width19.55%
ATR (14)0.2702 EUR
Vol Ratio (20d)0.95x
52W Range
2.56061% of range6.200
52W High6.200 EUR
52W Low2.560 EUR
Profitability
Gross Margin99.68%
EBITDA Margin0.00%
Profit Margin-7899.58%
Oper. Margin-6710.69%
ROE1241.63%
ROA-141.93%
Revenue Growth-89.90%
Earnings Growth—
Balance Sheet
Debt/Equity-2.10
Current Ratio3.16
Quick Ratio1.41
Book Value/Sh-0.1480 EUR
Cash/Share0.4810 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.207.65M
Float122.21M
Insiders14.05%
Institutions56.46%
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)9.974 EUR
Target Range7.000 EUR – 15.37 EUR
# Analysts5
Company
Market Cap998.79M EUR
Enterprise Value1.13B EUR
Revenue (TTM)6.76M EUR
Gross Profit6.74M EUR
Net Income (TTM)-354.14M EUR
Revenue/Share0.0360 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees69
Last Price4.775 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013233012